GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (NAS:PCRX) » Definitions » Cyclically Adjusted Book per Share

PCRX (Pacira BioSciences) Cyclically Adjusted Book per Share : $13.32 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Pacira BioSciences Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Pacira BioSciences's adjusted book value per share for the three months ended in Mar. 2025 was $17.253. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $13.32 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Pacira BioSciences's average Cyclically Adjusted Book Growth Rate was 12.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 19.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 33.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Pacira BioSciences was 52.70% per year. The lowest was 19.70% per year. And the median was 25.50% per year.

As of today (2025-05-15), Pacira BioSciences's current stock price is $25.60. Pacira BioSciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $13.32. Pacira BioSciences's Cyclically Adjusted PB Ratio of today is 1.92.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Pacira BioSciences was 43.97. The lowest was 0.95. And the median was 7.58.


Pacira BioSciences Cyclically Adjusted Book per Share Historical Data

The historical data trend for Pacira BioSciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences Cyclically Adjusted Book per Share Chart

Pacira BioSciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.69 7.51 9.37 11.25 12.89

Pacira BioSciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.89 12.31 12.61 12.89 13.32

Competitive Comparison of Pacira BioSciences's Cyclically Adjusted Book per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted PB Ratio falls into.


;
;

Pacira BioSciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pacira BioSciences's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=17.253/134.9266*134.9266
=17.253

Current CPI (Mar. 2025) = 134.9266.

Pacira BioSciences Quarterly Data

Book Value per Share CPI Adj_Book
201506 5.334 100.684 7.148
201509 5.690 100.392 7.647
201512 5.927 99.792 8.014
201603 6.096 100.470 8.187
201606 6.126 101.688 8.128
201609 5.731 101.861 7.591
201612 5.842 101.863 7.738
201703 6.762 102.862 8.870
201706 6.475 103.349 8.453
201709 6.528 104.136 8.458
201712 6.872 104.011 8.915
201803 6.840 105.290 8.765
201806 7.093 106.317 9.002
201809 7.337 106.507 9.295
201812 7.792 105.998 9.919
201903 7.932 107.251 9.979
201906 8.212 108.070 10.253
201909 8.301 108.329 10.339
201912 8.470 108.420 10.541
202003 8.881 108.902 11.003
202006 9.110 108.767 11.301
202009 13.499 109.815 16.586
202012 14.201 109.897 17.435
202103 14.805 111.754 17.875
202106 15.464 114.631 18.202
202109 16.140 115.734 18.817
202112 16.328 117.630 18.729
202203 15.746 121.301 17.515
202206 16.520 125.017 17.830
202209 16.791 125.227 18.092
202212 16.874 125.222 18.182
202303 16.707 127.348 17.701
202306 17.410 128.729 18.248
202309 17.911 129.860 18.610
202312 18.720 129.419 19.517
202403 19.179 131.776 19.638
202406 19.066 132.554 19.407
202409 16.243 133.029 16.475
202412 16.832 133.157 17.056
202503 17.253 134.927 17.253

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Pacira BioSciences  (NAS:PCRX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Pacira BioSciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=25.60/13.32
=1.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Pacira BioSciences was 43.97. The lowest was 0.95. And the median was 7.58.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Pacira BioSciences Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacira BioSciences Business Description

Traded in Other Exchanges
Address
5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Executives
Jonathan Slonin officer: Chief Clinical Officer C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Daryl Gaugler officer: Chief Operating Officer C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Marcelo Bigal director C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Michael J. Yang director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark Froimson director 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Kristen Marie Williams officer: CAO and General Counsel C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Paul J Hastings director 61 HARTFORD STREET, SAN FRANCISCO CA 94114
Lauren Bullaro Riker officer: Executive Director, Accounting C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Gary W Pace director C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Alethia Young director C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Abraham Ceesay director C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830
Roy Winston officer: Chief Clinical Officer C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Mark A. Kronenfeld director C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054
Reinhart Charles A. Iii officer: Chief Financial Officer C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054